Zydus Lifesciences

What Zydus Lifesciences does

Zydus Lifesciences Limited is a vertically integrated Indian pharmaceutical company headquartered in Ahmedabad and ranked 4th in the Indian pharmaceutical industry, operating across the full drug value chain from active pharmaceutical ingredient (API) manufacturing through formulations, biosimilars, vaccines, and novel chemical entities. Its product portfolio includes proprietary innovations such as Lipaglyn (Saroglitazar) — the first NCE from an Indian research pipeline — Exemptia (world's first biosimilar of Adalimumab), Twinrab (world's first novel rabies monoclonal antibody cocktail), and Vaxiflu-4 (India's first tetravalent inactivated influenza vaccine), alongside a broad generic and specialty portfolio. Recent additions include generic semaglutide (Semaglyn, Alterme, Mashema) launched after the March 2026 patent cliff, biosimilars Tishtha (Nivolumab) and Anyra (Aflibercept), and the FDA-approved ROLVEDON acquired via the $166.4 million Assertio Holdings deal that also delivered over 170 US community oncology accounts.

The company generates revenue through five primary streams: India branded formulations (~43% of consolidated revenue, distributed via medical representatives across primary health centers to tertiary hospitals), US generics (over 40 launches annually targeted, with single-digit growth guided), consumer wellness (61% YoY growth to ₹1,463 crore in Q4 FY26), fermentation-based APIs (acquired via Sterling Biotech), and emerging-markets specialty and oncology. FY26 revenue reached ₹27,148 crore (up 16.8% YoY) with ₹5,040 crore net profit; the go-to-market combines direct sales forces in India and US specialty oncology with channel partnerships and wholly-owned subsidiaries across 25+ emerging markets, France, Spain, Latin America, and South Africa. Manufacturing spans more than 30 plants across India (Gujarat, Maharashtra, Goa, Himachal Pradesh, Sikkim), the US, and Brazil, regulated by USFDA, EMA, and WHO-GMP — though the Baddi facility received a USFDA Warning Letter in June 2026 over purified talc observations, and the Ahmedabad biologics Unit 9 received seven observations during an April-May 2026 inspection.

Name

Zydus Lifesciences

Legal name

Zydus Lifesciences Limited

Website

https://zyduslife.com

Company type

Public

Founded year

1952

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Zydus Lifesciences is India's 4th-largest, vertically integrated pharmaceutical company (founded 1952) developing, manufacturing, and commercializing APIs, branded generics, biosimilars, vaccines, and novel drugs across India, the US, Europe, Latin America, and 25+ emerging markets.

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industry

Post-Approval Clinical Development (Phase IV & Lifecycle Management) (HLAIALAJ)

Keywords

• Pharmaceutical formulations
• Generic drug manufacturing
• Biologics and biosimilars
• Active pharmaceutical ingredients
• Vaccine development

Headquarters

HQ city

Ahmedabad

HQ country

India

HQ region

Asia

Offices11 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. India Formulations: Domestic pharmaceutical formulations business accounting for approximately 43% of consolidated revenues. Includes branded generics, acute and chronic therapies across multiple therapeutic areas.
2. North America (US Generics): Formulations revenue from US market with North America business expected to see single-digit growth aided by specialty and oncology portfolio expansion.
3. Consumer Wellness: Consumer wellness segment showed 61% YoY revenue growth to ₹1,463 crore in Q4 FY26, emerging as key growth driver.
4. Active Pharmaceutical Ingredients (API): API manufacturing including fermentation-based APIs through Sterling Biotech acquisition. Strategic focus on high-margin fermentation APIs with high entry barriers.
5. Biosimilars and Specialty: Specialty and oncology business including biosimilars like Tishtha (Nivolumab) and Anyra (Aflibercept), with plans for Saroglitazar US launch in Q4 FY27.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Core offering

Zydus Lifesciences is a fully integrated global pharmaceutical company that discovers, develops, manufactures, and commercializes a wide range of pharmaceutical products across the entire value chain—from active pharmaceutical ingredients (APIs) and formulations to biosimilars, vaccines, novel chemical entities (NCEs), and consumer wellness products. The company's portfolio spans therapeutic areas including oncology, cardiology, diabetology, immunology, infectious diseases, and rare diseases, with more than 30 manufacturing plants worldwide and research operations spanning 1,500 researchers across 19 sites.

Product overview

Zydus Lifesciences operates as a comprehensive pharmaceutical company offering a diversified portfolio of innovative drugs, biosimilars, and vaccines. The company's core offerings include novel drugs like Lipaglyn (first Indian NCE), world-first biosimilars like Exemptia (Adalimumab), innovative vaccines like Vaxiflu-4 and Twinrab (rabies mAbs), and an expanding oncology portfolio. Following the Assertio acquisition, Zydus gained access to specialty oncology products including ROLVEDON and over 170 community oncology accounts. The company has also entered the GLP-1 market with generic semaglutide products (Semaglyn, Alterme, Mashema) and launched biosimilars Tishtha (Nivolumab) and Anyra (Aflibercept). With over 29000 employees and operations across India, US, Brazil and other markets, Zydus positions itself as a leading innovator in the Indian pharmaceutical industry ranking 4th nationally.

Differentiator

Problem solved

Functional benefit

Brands

• Exemptia: World's first biosimilar of Adalimumab for treating autoimmune disorders
• Lipaglyn
• Twinrab
• Vaxiflu-4
• Zydus Healthcare

Products and services

• Lipaglyn (Saroglitazar)

Quantifiable outcome

• Q4 FY26 revenue of ₹7,587 crore, up 16% YoY with EBITDA margin improvement to 33.7%
• +4 more outcomes

Named customers3 records

Segments6 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• Sunshine Healthcare LankacoreStrategic or Co-development Partner · 26 June 2026Zydus Lifesciences partnered with Sri Lanka's Sunshine Healthcare Lanka to establish 50:50 joint venture Zydus Sunshine Lifesciences for pharmaceutical manufacturing in Sri Lanka with total investment of over $20 million. Zydus invests up to $5 million for 50% equity. Facility to be built in Horana Export Processing Zone to strengthen local drug production, reduce import dependence, and improve access to medicines.
• Goa State GovernmentcoreStrategic or Co-development Partner · 13 June 2026Goa government partnered with Zydus Healthcare (wholly-owned subsidiary) for 'Liver Forever' screening program to screen 300,000 people over 3 years for fatty liver disease (MAFLD/MASH). Integration into state's healthcare program at primary health centers, CHCs, and Goa Medical College.
• Sakar HealthcareminorChannel Partner/ Reseller/ Distributor · 21 May 2026Sakar Healthcare signed agreement with Zydus Lifesciences to supply oncology products across GCC countries and other emerging markets. Partnership brings total anti-cancer agreements to 40 globally for Sakar, strengthening Zydus distribution network in emerging markets.
• Assertio Holdings Inc.coreStrategic or Co-development Partner · 13 May 2026Zydus acquired US-based Assertio Holdings for $166.4 million through tender offer followed by merger. Acquisition provides Zydus with established US specialty oncology commercial platform, FDA-approved asset ROLVEDON (eflapegrastim-xnst), and over 170 community oncology accounts. Assertio's board deemed Zydus offer superior to competing Garda Therapeutics bid.
• Agenus Inc.minorStrategic or Co-development Partner · 11 May 2026Agenus received $91 million upfront payment from Zydus collaboration in Q1 2026, contributing to Agenus's profitable quarter. Collaboration involves BOT+BAL Phase 3 trial in refractory colorectal cancer with Zydus partnership providing development funding.
• Bayer (South East Asia) PTE LimitedminorStrategic or Co-development Partner · 7 May 2026Amendment in Joint Venture Agreement with Bayer (South East Asia) PTE Limited, indicating ongoing partnership in joint venture operations.
• Beihai BiotechcoreStrategic or Co-development Partner · 14 February 2025Zydus and Beihai Biotech signed exclusive licensing, supply and commercialization agreement for BEIZRAY (Albumin Solubilized Docetaxel Injection), a 505(B)(2) product for the US market. This strengthens Zydus differentiated product portfolio for US regulated market.
• Sterling BiotechcoreStrategic or Co-development Partner · 17 September 2024Zydus acquired Sterling Biotech's active pharmaceutical ingredients (API) manufacturing business for ₹84 crore ($10 million), completed by December 31, 2024. Acquisition focuses on fermentation-based API products with high entry barriers and attractive margins, aligning with Zydus's strategic expansion in high-margin fermentation APIs.

Scale indicators14 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Sun Pharmaceutical Industries: India's largest pharmaceutical company, competing directly with Zydus across branded generics in India, US generics, and specialty/innovation therapies. Both companies have similar global footprints with significant US exposure and India-domestic leadership positions.
• Dr. Reddy's Laboratories: Indian multinational with parallel operations in global generics, biosimilars, and proprietary products including APIs and formulations. Competes head-to-head with Zydus in US generics, emerging markets, and increasingly in differentiated/complex generics and biosimilars.
• Cipla: Major Indian pharmaceutical peer with strong domestic market share and expanding presence in complex generics, biosimilars, and specialty segments. Comparable in domestic formulations dominance, US generics presence, and emerging markets footprint to Zydus.
• Lupin Limited: Indian pharma peer competing in US generics, India branded formulations, and specialty/API manufacturing. Overlaps with Zydus across cardiovascular, diabetes, and infectious disease therapies, with similar regulatory and manufacturing profiles.
• Aurobindo Pharma: Indian pharmaceutical manufacturer with substantial US generics business, API manufacturing, and emerging markets presence. Competes with Zydus across multiple therapeutic areas and dosage forms in regulated and semi-regulated markets.
• Biocon Limited: Indian biopharmaceutical peer focused on biosimilars, biologics, and research services with significant overlap in biosimilar monoclonal antibodies and insulin products. Both companies have invested heavily in biologics manufacturing and global biosimilar commercialization.
• Glenmark Pharmaceuticals: India-headquartered specialty and generics pharmaceutical company with focus on dermatology, respiratory, and oncology segments. Overlaps with Zydus in India branded formulations, US specialty, and emerging markets distribution.
• Torrent Pharmaceuticals: Indian pharmaceutical company with similar therapeutic area focus (cardiology, CNS, diabetes) and comparable India domestic and international formulations business. Both rank among top 10 Indian pharmaceutical companies with parallel growth trajectories.

Broad incumbents

• Teva Pharmaceutical Industries: World's largest generics manufacturer and a major incumbent in US generics and specialty markets. Competes with Zydus broadly across US generics portfolios, biosimilars, and specialty therapies, though at much larger scale with broader geographic diversification.

Emerging players

• Amneal Pharmaceuticals: US-focused specialty and generics pharmaceutical company with comparable portfolio in complex generics, injectables, and biosimilars. Competes with Zydus in US generics and specialty segments, with similar focus on affordable therapeutics and US manufacturing capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/zydusuniverse
• YouTubeyoutube.com/channel/UCI_plFGyaPT631UONG4ajUQ
• Facebookfacebook.com/163560647038950
• LinkedInlinkedin.com/company/zyduscadila
• Instagraminstagram.com/zydusuniverse

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries10 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A6 records

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zydus Lifesciences